INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Metropolis Healthcare on Monday made a decent market debut, as the scrip got listed at Rs 960 on BSE, a 9.09 per cent premium
over issue price of Rs 880 per share
The Rs 1,204 crore IPO, which was sold between April 3 to April 5, was subscribed 5.83 times.
At the issue price, the stock was valued at
of 39 times FY19 annualised earnings against Dr Lal Pathlabs’ 43 times.
Metropolis’ laboratory network consists of 115 clinical
laboratories, comprising a global reference laboratory located in Mumbai, 14 regional reference laboratories 56 satellite laboratories and
44 express laboratories.
The diagnostic company, which offers approximately 3,487 clinical laboratory tests and 530 profiles, has presence
across 19 states and a leadership position in West and South India through its network of 83 clinical laboratories, 1,473 patient touch
points and 396 ARCs (assisted referral centres) in the regions
The revenue from operations rose at a CAGR of 16.3 per cent to Rs 643.6 crore from FY16 to FY18, while profits climbed at a CAGR of 15.7
per cent to Rs 109.7 crore
The company is debt free.
In nine months to December 31, 2018, the diagnostic company conducted 12.3 million tests on 6.6 million patients
compared with 16 million tests on 7.7 million patients in in the entire FY18.
